biostudies-literatureUnknown27(8)Fakih MAmgen Inc<h4>Background</h4>The KRAS p.G12C mutation has recently become an actionable drug target. To further understand KRAS p.G12C disease, we describe clinicopathologic characteristics, treatment patterns, overall survival (OS), and real-world progression-free survival (rwPFS) in patients with metastatic colorectal cancer (mCRC), KRAS p.G12C mutations (KRAS G12C), and other KRAS mutations (KRAS non-G12C) using a de-identified database.<h4>Patients and methods</h4>Clinical and tumor characteristics, including treatments received, genomic profile, and clinical outcomes were assessed for patients from a US clinical genomic database with mCRC diagnosed between January 1, 2011, and March 31, 2020, with genomic sequencing data available.<h4>Results</h4>Of 6477 patients with mCRC (mCRC cohort), 238 (3The oncologist663-674https://www.ebi.ac.uk/biostudies/studies/S-EPMC9355827biostudies-literatureReal-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.PMC9355827Kopetz SFakih MAggarwal SRehn MChan EChia VTu HHsu HfalseReal-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.<h4>Background</h4>The KRAS p.G12C mutation has recently become an actionable drug target. To further understand KRAS p.G12C disease, we describe clinicopathologic characteristics, treatment patterns, overall survival (OS), and real-world progression-free survival (rwPFS) in patients with metastatic colorectal cancer (mCRC), KRAS p.G12C mutations (KRAS G12C), and other KRAS mutations (KRAS non-G12C) using a de-identified database.<h4>Patients and methods</h4>Clinical and tumor characteristics, including treatments received, genomic profile, and clinical outcomes were assessed for patients from a US clinical genomic database with mCRC diagnosed between January 1, 2011, and March 31, 2020, with genomic sequencing data available.<h4>Results</h4>Of 6477 patients with mCRC (mCRC cohort), 238 (32022-01-01T00:00:00Z2022 Aug2025-04-22T11:29:35.412Z2025-04-05T23:58:53.716ZS-EPMC93558273547217610.1093/oncolo/oyac077